Novavax (NVAX) Operating Income (QoQ) (2010 - 2026)

Novavax (NVAX) Operating Income (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Novavax 1.33 Bn 607.37 Mn 42.45 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -255.84%
Mar 31, 2026 -208.43%
Dec 31, 2025 107.99%
Sep 30, 2025 -276.13%
Jun 30, 2025 -80.39%
Mar 31, 2025 493.28%
Dec 31, 2024 2.19%
Sep 30, 2024 -183.24%
Jun 30, 2024 211.16%
Mar 31, 2024 21.10%
Dec 31, 2023 -46.12%
Sep 30, 2023 -326.54%
Jun 30, 2023 117.73%
Mar 31, 2023 -28.25%
Dec 31, 2022 -91.75%
Sep 30, 2022 73.66%
Jun 30, 2022 -330.76%
Mar 31, 2022 125.37%
Dec 31, 2021 -168.59%
Sep 30, 2021 11.19%